Exhibit 31.2

                                  CERTIFICATION

I, Michael Kanovsky, Ph.D., certify the following:

      1.    I have reviewed this annual report on Form 10-KSB of Amazon Biotech,
            Inc.;

      2.    Based on my knowledge, this annual report does not contain any
            untrue statement of a material fact or omit to state a material fact
            necessary to make the statements made, in light of the circumstances
            under which such statements were made, not misleading with respect
            to the period covered by this annual report;

      3.    Based on my knowledge, the financial statements, and other financial
            information included in this annual report, fairly present in all
            material respects the financial condition, results of operations and
            cash flows of Amazon Biotech, Inc. as of, and for, the periods
            presented in this annual report;

      4.    Amazon Biotech, Inc.'s other certifying officer and I are
            responsible for establishing and maintaining disclosure controls and
            procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for
            Amazon Biotech, Inc. and we have done the following:

            a.    designed such disclosure controls and procedures to ensure
                  that material information relating to Amazon Biotech, Inc. is
                  made known to us by others within the Company, particularly
                  during the period in which this annual report is being
                  prepared;

            b.    evaluated the effectiveness of Amazon Biotech, Inc.'s
                  disclosure controls and procedures as of a date within 90 days
                  prior to the filing date of this annual report (the
                  "Evaluation Date"); and

            c.    presented in this annual report our conclusions about the
                  effectiveness of the disclosure controls and procedures based
                  on our evaluation as of the Evaluation Date;

      5.    Amazon Biotech, Inc.'s other certifying officer and I have
            disclosed, based on our most recent evaluation, to Amazon Biotech,
            Inc.'s auditors and the audit committee of Amazon Biotech Inc.'s
            board of directors:

            a.    all significant deficiencies in the design or operation of
                  internal controls which could adversely affect Amazon Biotech,
                  Inc.'s ability to record, process, summarize and report
                  financial data and have identified for Amazon Biotech, Inc.'s
                  auditors any material weaknesses in internal controls; and

            b.    any fraud, whether or not material, that involves management
                  or other employees who have a significant role in Amazon
                  Biotech, Inc.'s internal controls; and

      6.    Amazon Biotech, Inc.'s other certifying officer and I have indicated
            in this annual report whether or not there were significant changes
            in internal controls or in other factors that could significantly
            affect internal controls subsequent to the date of our most recent
            evaluation, including any corrective actions with regard to
            significant deficiencies and material weaknesses.


November 12, 2004                           /s/ Michael Kanovsky, Ph.D.
                                            ------------------------------------
                                            [GRAPHIC OMITTED]
                                            Michael Kanovsky, Ph.D.
                                            President
                                            (Principal Financial Officer)


                                       1